• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Penn State Hershey Medical Center - Developmental Therapeutics Review - Q4 2010 Product Image

Penn State Hershey Medical Center - Developmental Therapeutics Review - Q4 2010

  • Published: December 2010
  • Region: Global
  • 34 pages
  • Global Markets Direct

Penn State Hershey Medical Center – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Penn State Hershey Medical Center - Developmental Therapeutics Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Penn State Hershey Medical Center - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Penn State Hershey Medical Center human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in READ MORE >



List of Tables
List of Figures
Penn State Hershey Medical Center Snapshot
Penn State Hershey Medical Center Overview
Key Information
Key Facts
Penn State Hershey Medical Center – Research and Development Overview
Key Therapeutic Areas
Penn State Hershey Medical Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Penn State Hershey Medical Center – Pipeline Products Glance
Penn State Hershey Medical Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Penn State Hershey Medical Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Penn State Hershey Medical Center – Drug Profiles
Carboplatin + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
anti-thymocyte globulin + busulfan + cyclophosphamide + fludarabine phosphate + melphalan + methylprednisolone
Product Description
Mechanism of Action
R&D Progress
aldesleukin + allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes + fludarabine phosphate
Product Description
Mechanism of Action
R&D Progress
anti-thymocyte globulin + busulfan + cyclosporine + melphalan + methotrexate + methylprednisolone
Product Description
Mechanism of Action
R&D Progress
anti-thymocyte globulin + graft-versus-tumor induction therapy + sargramostim + busulfan + cyclosporine + melphalan + methylprednisolone
Product Description
Mechanism of Action
R&D Progress
cytomegalovirus pp65-specific cytotoxic T lymphocytes
Product Description
Mechanism of Action
R&D Progress
Zoledronic acid + Gleevec
Product Description
Mechanism of Action
R&D Progress
Penn State Hershey Medical Center – Pipeline Analysis
Penn State Hershey Medical Center – Pipeline Products by Therapeutic Class
Penn State Hershey Medical Center Pipeline Products By Target
Penn State Hershey Medical Center – Pipeline Products by Route of Administration
Penn State Hershey Medical Center – Locations And Subsidiaries
Head Office
Recent Developments
May 17, 2010: Pharmatech Oncology Announces ASCO Abstracts
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS